随机临床试验:口服HIF-1α稳定剂GB004治疗溃疡性结肠炎的1b期研究
这项双盲、安慰剂对照的1b期研究将34例活动性溃疡性结肠炎患者按2:1随机分配,接受GB004 120 mg口服溶液或安慰剂每日一次治疗28天。GB004总体耐受良好,未发生治疗相关严重不良事件或死亡;探索性分析显示GB004组在第28天多项疾病活动度改善指标上数值上高于安慰剂组。
要点
- GB004 120 mg每日一次治疗28天在活动性溃疡性结肠炎患者中总体耐受良好。
- 不良反应发生率:安慰剂组27.3%(3/11),GB004组39.1%(9/23);恶心和味觉障碍在GB004组更常见。
- 探索性分析显示GB004组第28天多项疾病活动度改善指标数值上高于安慰剂组。
核心结论
- 这项1b期试验结果支持进一步评估GB004治疗溃疡性结肠炎的全部治疗潜力。
- 一项2期研究(NCT04556383)正在进行中。
研究设计与样本
- 双盲、安慰剂对照研究,将患者按2:1随机分配接受GB004 120 mg口服溶液或安慰剂每日一次治疗28天。
- 纳入标准为Robarts组织病理学指数评分≥4且上皮内中性粒细胞浸润、Mayo临床总评分3-12、Mayo内镜子评分≥1、便血,且既往接受过5-氨基水杨酸类、皮质类固醇或免疫抑制剂治疗。
- 共随机分配34例患者。
主要发现
- 不良事件发生率:安慰剂组27.3%(3/11),GB004组39.1%(9/23)。
- 恶心在GB004组发生率为21.7%(5/23),安慰剂组为0%;味觉障碍在GB004组发生率为13.0%(3/23),安慰剂组为0%。
- 未发生治疗相关严重不良事件或死亡。
- GB004表现出极小蓄积,结肠浓度高于血浆浓度。
- 探索性药效学和疗效分析显示GB004达到靶点结合,且第28天GB004组在多项疾病活动度改善指标上达到改善的患者比例数值上高于安慰剂组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epithelial barrier dysfunction contributes to a dysregulated intestinal immune response in ulcerative colitis (UC). GB004 is an orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α, a transcription factor with protective roles at the epithelial layer of the inflamed gut. AIMS: To evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of GB004 in patients with active UC. METHODS: This double-blind, placebo-controlled study randomised patients 2:1 to receive an oral solution of GB004 120 mg or placebo once daily for 28 days. Eligible patients had a Robarts Histopathology Index score ≥4 with neutrophils in the epithelium, total Mayo Clinic score 3-12, Mayo Clinic endoscopic subscore ≥1, and blood in the stool, despite treatment with 5-aminosalicylates, corticosteroids or immunosuppressants. RESULTS: Thirty-four patients were randomised. GB004 120 mg for 28 days was generally well-tolerated. Adverse events occurred in 27.3% (3/11) and 39.1% (9/23) of patients in the placebo and GB004 groups respectively. Nausea and dysgeusia were most commonly reported in the GB004 group (0% for placebo and 21.7% [5/23] and 13.0% [3/23] respectively for GB004). There were no treatment-related serious adverse events or deaths. GB004 exhibited minimal accumulation, with higher colonic concentrations relative to plasma. Exploratory pharmacodynamic and efficacy analyses demonstrated GB004 target engagement and numerically higher proportions of patients achieving improvement in multiple measures of disease activity, respectively, at day 28 for GB004 compared to placebo. CONCLUSION: Results from this phase 1b trial support evaluation of the full therapeutic potential of GB004 for the treatment of UC. A phase 2 study (NCT04556383) is ongoing. Clinicaltrials.gov NCT03860896.
引用
- Danese S, Levesque BG, Feagan BG, et al. Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis. Aliment Pharmacol Ther. 2022. PMID: 35014040. doi:10.1111/apt.16753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。